Clinical Trial

A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma

Study acronym: CN-CLCNEC
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Cervical large cell neuroendocrine carcinoma (LCNEC) exhibits highly aggressive biological behavior, including strong invasiveness, a high propensity for metastasis, drug resistance, and poor prognosis, necessitating heightened clinical and pathological awareness. This study aims to summarize the clinical characteristics of LCNEC and analyze various prognostic factors to enhance understanding and vigilance toward this disease. Combined with precise pathological diagnosis, improving diagnostic accuracy is crucial for formulating treatment strategies and assessing patient prognosis.
Trial Details
NCT Number NCT07240753
Lead Sponsor Lili
Collaborators: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Cancer Research Institute of Zhongshan City, The First Affiliated Hospital of Zhengzhou University, Qilu Hospital of Shandong University, Fujian Province Tumor Hospital, Fujian Maternity and Child Health Hospital, Zhejiang Cancer Hospital, The Third Affiliated Hospital of Kunming Medical College., Obstetrics & Gynecology Hospital of Fudan University, Women's Hospital School Of Medicine Zhejiang University, National Cancer Center, China, Peking Union Medical College Hospital, The Affiliated Tumor Hospital of Xinjiang Medical University, The First Affiliated Hospital of Anhui Medical University, Tianjin Medical University Cancer Institute and Hospital, Renmin Hospital of Wuhan University
Conditions Uterine Cervical Neoplasms
Enrollment 200 participants
Start Date 2025-12-01
Primary Completion 2028-11-01 (estimated)
Study Completion 2028-11-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-21